| 赵永艳,刘莹莹,吴胜英.养血清脑颗粒治疗血管性痴呆大鼠的实验研究[J].安徽医药,2022,26(6):1102-1106. |
| 养血清脑颗粒治疗血管性痴呆大鼠的实验研究 |
| Experimental study of Yangxue Qingnao granule in treating rats with vascular dementia |
| |
| DOI：10.3969/j.issn.1009-6469.2022.06.009 |
| 中文关键词: 中草药 养血清脑颗粒 痴呆，血管性 5-羟色胺 β-连环素 胶质纤维酸性蛋白 血管内皮生长因子 大鼠， Sprague-Dawley |
| 英文关键词: Drugs, Chinese herbal Yangxue Qingnao granule Dementia, vascular 5-hydroxytryptamine β-catenin Glial fibrillary acidic protein Vascular endothelial growth factor Rats, Sprague-Dawley |
| 基金项目: |
|
| 摘要点击次数: 837 |
| 全文下载次数: 355 |
| 中文摘要: |
| 目的研究养血清脑颗粒对大鼠血管性痴呆的治疗机制。方法该研究起止时间为 2019年 2—6月。 24只 SD大鼠采用两血管阻断法制作血管性痴呆模型，以随机数字表法分为模型组和实验组，每组 12只，另取 12只未造模鼠设为对照组。实验组每日按 20 mL·kg?1·d?1的剂量分 2次用 6.4%的养血清脑颗粒混悬液灌胃治疗 3周，模型组和对照组灌等体积生理盐水对照。治疗结束后采用 Morris水迷宫分析系统分析大鼠学习和记忆能力，用 Zea Longa神经行为学评分评定治疗效果。然后处死大鼠，检测各组大鼠血清 S100B蛋白(S100B)及脑海马 CA1区 5-羟色胺含量、血管内皮生长因子(VEGF)胶质纤维酸性蛋白(GFAP)及 β-连环素( β-catenin)的表达。结果对照组逃避潜伏期为［(41.24±3.49)s］跨越平台次数为［(6.0、5±0.27)次］，Zea Longa评分为［( 0.04±0.00)分］，与对照组相比，模型组逃避潜伏期［( 86.95±6.34)s］明显延，长( P<0.05)，跨越平台次数［( 2.92± |
| 英文摘要: |
| Objective To study the therapeutic mechanism of Yangxue Qingnao granule on rats with vascular dementia.Methods This study started from February 2019 to the end of June 2019. During the experiment, 24 SD rats were used to make a vascular dementia model by the modified vascular occlusion method, and were randomly divided into a model group and an experimental group by therandom number table method, with 12 mice in each group. Another 12 unmodeled mice were selected as the control group. The experimental group was given 6.4% Yangxue Qingnao granule suspension twice a day at the dose of 20 mL·kg?1·d?1 for 3 weeks with, and themodel group and the control group were given an equal volume of normal saline. After treatment, the Morris water maze analysis systemwas used to analyze the learning and memory abilities of the rats, and the Zea Longa neurobehavioral score was used to evaluate thetherapeutic effect. Then all rats were sacrificed, and serum S100B protein (S100B), hippocampal CA1 and 5-hydroxytryptamine content, vascular endothelial growth factor (VEGF), glial fibrillary acidic protein (GFAP) and β-catenin (β-catenin) in each group of rats were detected.Results The escape latency of the control group was [(41.24±3.49) s], the number of crossing platforms was [(6.05±0.27) n], and the Zea Longa score was [(0.04±0.00) s]. Compared with the control group, the escape latency of the model group [(86.95 ±6.34) s] was significantly prolonged (P<0.05), the number of platform crossings [(2.92 ± 0.14) times] was decreased (P<0.05), and the Zea Longa score [(3.84 ± 0.31) points] was significantly increased (P<0.05); the serum S100B in the control group was [(2.41±0.21) mg/L], the GFAP protein in the hippocampal CA1 area was [(10.84±0.89) pcs/high magnification field of view], and the 5-hydroxytryptamine content in the hippocampal CA1 area was [(0.74) ±0.09) μg/L], compared with the control group, the expression of serum S100B[(5.29±0.37) mg/L] and GFAP protein [(35.53±2.18) pcs/high magnification field of view] in the hippocampus CA1 region of the modelgroup were increased (P<0.05), the content of 5-hydroxytryptamine in hippocampal CA1 area [(0.51±0.05) μg/L] decreased (P<0.05); VEGF in hippocampal CA1 area of control group was [(150.59±7.53) mg/L], β -catenin protein was [(9.97±1.09) pcs/high magnificationfield of view], compared with the control group, VEGF [(151.82±7.35) mg/L], β-catenin protein [(10.08±1.20) pcs/high magnificationfield of view] ,There was no statistically significant difference in the expression of cells/high power field (P>0.05). Compared with the model group, the number of crossing platforms [(5.75 ± 0.39) times] in the experimental group increased (P<0.05), the escape latency [(42.57 ± 3.20) s] was shortened (P<0.05), and the Zea Longa score [(1.91 ± 0.21) points], S100B [(2.85±0.34) mg/L] and GFAP protein[(21.45±1.49) pcs/high magnification field of view] were significantly decreased (P<0.05). The expressions of 5-hydroxytryptamine content [(0.74±0.09) μg/L], VEGF [(193.25±16.34) mg/L] and β-catenin protein [(12.40±1.56) pcs/high magnification field of view] and CA1 regions were all increased (P<0.05).Conclusion Yangxue Qingnao granule may play a therapeutic role in vascular dementia by up-regulating β-catenin protein, promoting VEGF and 5-hydroxytryptamine synthesis, reducing GFAP and improving brain blood flow. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
